TKNO Earnings

TKNO reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 9.80M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.09 by 0%. The stock experienced a 13.16% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following TKNO's earnings announcement on 2026-02-26, the stock price moved by 13.16% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, TKNO's stock price tends to shift by an average of 8.75% in the 10 days leading up to earnings and -2.82% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate TKNO's annual revenue to reach 10.68M, while the EPS is projected at -0.09. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TKNO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TKNO's stock price typically moves by 8.75% in the 10 days before its earnings and -2.82% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.09 and revenue of 10.68M.

The earnings call highlights a strong financial performance with a 15% revenue increase and improved gross margins. Despite the acknowledgment of risks in forward-looking statements, the company's ability to achieve a 40% increase in net income and a 20% rise in cash flow indicates strong operational efficiency. The lack of specific concerns in the Q&A section further supports a positive sentiment. Although there are uncertainties in the biopharma funding environment, the overall financial health and growth initiatives suggest a positive stock price movement in the near term.